Soon after the dawn of the 21st Century, women in Europe had access to a new type of menopause treatment. Since September of 2007, that same treatment has been made available to women of the United States.
It is called “Amberen.” In creating Amberen, scientists found a way to fashion an analogue of the goanadotropin releasing hormone (GnRH). The hypothalamus of a female puts out GnRH when it wants the pituitary gland to release luteinizing hormone and follicle stimulating hormone (FSH).
Amberen contains salts of succinate, the product of a natural biochemical reaction. That reaction takes place at a low level in young pre-adolescent females. When a young girl reaches the age of puberty, then her hypothalamus begins to produce larger amounts of GnRH. Amberen helps to treat the symptoms associated with menopause by stimulating the hypothalamic-pituitary-ovarian axis. That stimulation leads to production of estrogen. An older woman can thus have an estrogen level that mimics the estrogen level in a young pre-menopausal female.
By using Amberen, a woman can counter the physical, biochemical and neurovegetative changes that create problems for many women, as they pass through perimenopause and menopause. This article begins a series of articles about the difficulties experienced by women as they suffer a severe decline in the level of their GNRH, and as they loose their ability to produce estrogen.